Level Four Advisory Services’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Level Four Advisory Services’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-1,069	Closed	-$235K	–	665
2020 Q4	$235K	Buy	+1,069	New	+$231K	0.02%	523

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Level Four Advisory Services's MRTX Position: Q1 2021 in Review

Level Four Advisory Services sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2021, closing a stake of 1,069 shares — an estimated $235K sold.

Level Four Advisory Services first reported a position in MRTX in Q4 2020 and held it in 1 quarter. The position peaked at $235K in Q4 2020. 260 funds tracked by Wall St. Rank hold MRTX as of Q1 2021.

Level Four Advisory Services reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Level Four Advisory Services sold 1,069 Mirati Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $235K.
Level Four Advisory Services first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Level Four Advisory Services's Mirati Therapeutics, Inc. Common Stock position peaked at $235K in Q4 2020.
260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2021.

Based on Level Four Advisory Services's 13F filing for Q1 2021, filed 10 May 2021.